67337-79-5

Basic information

• Product Name: 2-O,3-O,4-O,6-O-Tetraacetyl-α-L-glucopyranosyl bromide
• Synonyms: 2-O,3-O,4-O,6-O-Tetraacetyl-α-L-glucopyranosyl bromide
• CAS NO: 67337-79-5
• Molecular Formula: C₁₄H₁₉BrO₉
• Molecular Weight: 411.19926
• Mol File: 67337-79-5.mol
• Article Data: 114

Chemical Properties

• Melting Point: 87-88 °C
• Boiling Point: 412.0±45.0 °C(Predicted)
• Appearance: /
• Density: 1.49±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 2-O,3-O,4-O,6-O-Tetraacetyl-α-L-glucopyranosyl bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-O,3-O,4-O,6-O-Tetraacetyl-α-L-glucopyranosyl bromide(67337-79-5)
• EPA Substance Registry System: 2-O,3-O,4-O,6-O-Tetraacetyl-α-L-glucopyranosyl bromide(67337-79-5)

Safety Data

• Hazardous Substances Data: 67337-79-5(Hazardous Substances Data)

Upstream product

• 572-09-8 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide 
• 2280-44-6 D-Glucose 
• 506-96-7 Acetyl bromide 
• 3947-62-4 2,3,4,5-tetra-O-acetyl-D-glucopyranose 
• 83-87-4 D-glucose pentaacetate 
• 108-24-7 acetic anhydride 
• 604-69-3 β-D-glucose pentaacetate 
• 3947-62-4 2,3,4,6-tetraacetylglucose 
• 604-68-2 α-D-glucopyranose peracetylate 
• 492-61-5 β-D-glucose 
• 492-62-6 alpha-D-glucopyranose 
• 13992-16-0 phenyl 2,3,4,6-tetra-O-acetyl-1-thio-α,β-D-glucopyranoside 
• 83-87-4 D-Mannose pentaacetate 
• 83-87-4 β-D-mannopyranose pentaacetate 

Downstream Products

• 572-09-8 tetra-O-acetyl-glucopyranosyl bromide 
• 138626-04-7 4'-O-benzoylphloracetophenone 2'-O-(tetra-O-acetyl-β-L-glucopyranoside) 
• 188783-55-3 Acetic acid (2R,3S,4R,5S,6S)-4,5-diacetoxy-6-acetoxymethyl-2-(bis-benzyloxy-phosphoryloxy)-tetrahydro-pyran-3-yl ester 
• 220984-78-1 benzyl 2,3,4,6-tetra-O-acetyl-β-L-glucopyranoside 
• 680187-72-8 7-O-(2,3,4,6-tetra-O-acetyl-β-L-glucopyranosyl)naringenin 
• 2873-29-2 3,4,6-tri-O-acetyl-1,5-anhydro-2-deoxy-L-arabino-hex-1-enitol 
• 926924-55-2 C₃₂H₄₁O₁₄N 
• 912847-95-1 2,6-anhydro-3,4,5-tri-O-benzyl-D-glucose 
• 912847-94-0 1,5-anhydro-2,3,4-tri-O-benzyl-L-glucitol 
• 912847-93-9 1,5-anhydro-2,3,4,6-tetra-O-benzyl-L-glucitol 
• 912847-99-5 2-((2,3,4-tri-O-benzyl-β-D-xylopyranosyl)methyl)naphthalene 
• 141434-71-1 1,5-anhydro-L-glucitol 
• 595564-88-8 5,4'-dihydroxy-7-O-β-D-glucopyranosyloxyflavone 
• 679398-71-1 7-O-(2,3,4,6-tetra-O-acetyl-β-L-glucopyranosyl)apigenin 

Relevant articles and documents

Design, Synthesis, biological investigations and molecular interactions of triazole linked tacrine glycoconjugates as Acetylcholinesterase inhibitors with reduced hepatotoxicity

Tacrine is a known Acetylcholinesterase (AChE) inhibitors having hepatotoxicity as main liability associated with it. The present study aims to reduce its hepatotoxicity by synthesizing tacrine linked triazole glycoconjugates via Huisgen's [3 + 2] cycloaddition of anomeric azides and terminal acetylenes derived from tacrine. A series of triazole based glycoconjugates containing both acetylated (A-1 to A-7) and free sugar hydroxyl groups (A-8 to A-14) at the amino position of tacrine were synthesized in good yield taking aid from molecular docking studies and evaluated for their in vitro AChE inhibition activity as well as hepatotoxicity. All the hybrids were found to be non-toxic on HePG2 cell line at 200 μM (100 % cell viability) as compared to tacrine (35 % cell viability) after 24 h of incubation period. Enzyme kinetic studies carried out for one of the potent hybrids in the series A-1 (IC50 0.4 μM) revealed its mixed inhibition approach. Thus, compound A-1 can be used as principle template to further explore the mechanism of action of different targets involved in Alzheimer's disease (AD) which stands as an adequate chemical probe to be launched in an AD drug discovery program.

Synthesis of malformin-A1, C, a glycan, and an aglycon analog: Potential scaffolds for targeted cancer therapy

Improvement in therapeutic efficacy while reducing chemotherapeutic side effects remains a vital objective in synthetic design for cancer treatment. In keeping with the ethos of therapeutic development and inspired by the Warburg effect for augmenting biological activities of the malformin family of cyclic-peptide natural products, specifically anti-tumor activity, a β-glucoside of malformin C has been designed and synthesized utilizing precise glycosylation and solution phase peptide synthesis. We optimized several glycosylation procedures utilizing different donors and acceptors. The overarching goal of this study was to ensure a targeted delivery of a glyco-malformin C analog through the coupling of D-glucose moiety; selective transport via glucose transporters (GLUTs) into tumor cells, followed by hydrolysis in the tumor microenvironment releasing the active malformin C a glycon analog. Furthermore, total synthesis of malformin C was carried out with overall improved strategies avoiding unwanted side reactions thus increasing easier purification. We also report on an improved solid phase peptide synthesis protocol for malformin A1.

GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE

The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.